Emerging data suggest this peptide, a dual stimulator targeting both incretin and GIP , appears to represent a promising advancement for weight treatment. Initial clinical trials have demonstrated impressive decreases in visceral mass , possibly exceeding other obesity therapies . However , further assessment is necessary to completely assess its l